News from neurologylive.comFollowNews from neurologylive.comSee all of neurologylive.com’s headline news. Compare how the top news stories are covered by left-wing and right-wing news sources.We’ve discovered 333 headlines written by neurologylive.com during the past 3 months. Ground News rates neurologylive.com’s media bias as . . Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check. neurologylive.com’s factuality rating is Unknown. Ground News calculates this rating using a combination of the fact and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.Follow See all of neurologylive.com’s headline news. Compare how the top news stories are covered by left-wing and right-wing news sources. We’ve discovered 333 headlines written by neurologylive.com during the past 3 months. Ground News rates neurologylive.com’s media bias as . . Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check. neurologylive.com’s factuality rating is Unknown. Ground News calculates this rating using a combination of the fact and reliability ratings from Ad Fontes Media and Media Bias/Fact Check. Information about neurologylive.comWhere is neurologylive.com located?neurologylive.com's WebsiteMedia Bias RatingsDo you diasgree? Edit biasLearn more about Media Bias Ratings.FactualityAverage Factuality Rating: UnknownLearn more about Factuality Ratings.Top neurologylive.com NewsUnited States · United StatesUS FDA approves PTC Therapeutics’ gene therapy for ultra-rare disorder100% Center coverage: 1 sources(Reuters) – The U.S. Food and Drug Administration approved PTC Therapeutics’ gene therapy that is administered directly in the brain to treat a potential fatal enzyme deficiency disorder, the company said on Wednesday. (Reporting by Sriparna Roy, Leroy Leo and Christy Santhosh in Bengaluru; Editing by Maju Samuel)See the StoryParkinson's DiseaseParkinson Immunotherapy ACI-7104.056 Demonstrates Positive Antibody Responses in Phase 2 Trial UpdateAfter just 6 weeks of treatment, patients showed antibody levels 16 times higher than those in the placebo group, highlighting the vaccine’s potential to slow disease progression.See the StoryNew Haven, Connecticut · New HavenEvolution of Multiple Sclerosis Diagnostic Criteria and the Role of Spinal Taps: David A. Hafler, MD, FANAThe William S. and Lois Stiles Edgerly Professor of Neurology at Yale School of Medicine talked about the ongoing evolution of multiple sclerosis diagnostic criteria and the importance of comprehensive testing to guide early intervention and improve outcomes. [WATCH TIME: 5 minutes]See the StoryLatest News StoriesTopics Most Covered by neurologylive.comParkinson's DiseaseMultiple SclerosisDisabilityFDAHealthParkinson's DiseaseMultiple SclerosisDisabilitySources Covering Similar TopicspipelinereviewPharmacy Timescontemporarypediatrics.comlifesciencesbc.cahcplive.compipelinereviewPharmacy Timescontemporarypediatrics.comSuggest a sourceLooking for a source we don't already have? Suggest one here.You've scrolled to the bottom of the feed, there are no more stories.
